Targeted Oncology Staff

During a live virtual event, Ann LaCasce, MD, MMSc, discusses third-line treatment options for diffuse large B-cell lymphoma when considering eligibility for chimeric antigen receptor T-cell therapy.

Twenty-two days following transplantation, a patient with graft-versus-host disease presented with new symptoms.

During a Targeted Oncology Case-Based Roundtable event, Chul Kim, MD, MPH, assistant professor at Georgetown University, discussed immunotherapy options for patients with non–small cell lung cancer with PD-L1 expression.

During a live virtual event, Saad Zafar Usmani, MD, discussed 2 studies of drug combinations in patients with multiple myeloma with or without stem cell transplants.

During a live virtual event, Ulka Vaishampayan, MBBS, discussed the results of the CLEAR trial of lenvatinib and pembrolizumab compared with sunitinib in first-line treatment of advanced RCC.

During a live virtual event, Joyce O'Shaughnessy, MD, discussed participants' experiences with the tolerability of sacituzumab govitecan in patients with metastatic triple-negative breast cancer. The participants also discussed their approaches to molecular testing for biomarkers at the time of disease relapse or progression.

During a live virtual event, Joyce O'Shaughnessy, MD, discussed treatment options for a patient with metastatic triple-negative breast cancer whose disease recurred 8 months after receiving adjuvant therapy.

During a live virtual event, Ravi Salgia, MD, PhD, discussed how to decide whether to use a MET inhibitor in the first line and whether to switch to a MET inhibitor from other treatments.

Richard S. Finn, MD discusses a 77-year-old White woman who presented with complaints of abdominal pain and fatigue.

A 51-year-old man presented with pallor and worsening fatigue on exertion but had adequate liver and heart function.

During a live virtual event, Sandy Srinivas, MD, discussed the tolerability of the tyrosine kinase inhibitor/immunotherapy combinations cabozantinib plus nivolumab and lenvatinib plus pembrolizumab, compared with the dual immunotherapy ipilimumab plus nivolumab.

Based on the case of a 59-year-old Asian man with non-small cell lung cancer, Jason Niu, MD discusses the targeted therapy options for the disease.

For a 41-year-old female patient with diffuse large B-cell lymphoma, multiple treatment options exists. Elizabeth A. Brem, MD discussed the options during an interview with Targeted Oncology.

During a live virtual event, Paolo Caimi, MD, discussed the barriers to using loncastuximab tesirine for diffuse large B-cell lymphoma preceding chimeric antigen receptor T-cell therapy.

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline treatment options for patients with chronic lymphocytic leukemia, with questions by Targeted Oncology.

During a live virtual event, Richard S. Finn, MD, discussed the process of selecting frontline treatment for hepatocellular carcinoma including liver and kidney transplants and immunotherapy agents.

A 51-year-old man presented with pallor and worsening fatigue on exertion.

During a live virtual event, Sandy Srinivas, MD, discussed results from the CLEAR trial of lenvatinib and pembrolizumab in renal cell carcinoma and the participants' experiences with the regimen including dose reductions needed by their patients across multiple cancer types.

Two years after being diagnosed with multiple myeloma and being treated, a patient reported mild fatigue but continued to work full time.

Joel Neal, MD, PhD and Karen Kelly, MD recently teamed up to moderate a roundtable discussion around molecular testing and choice of treatment for a 59-year-old patient with non–small cell lung cancer.

During a live virtual event, Ravi Salgia, MD, PhD, discussed issues with molecular testing and biopsies including delays and affordability, plus identifying and responding to rare mutations detected by molecular testing.

During a live virtual event, Paolo Caimi, MD, discussed the toxicity and dosage of loncastuximab tesirine as a third-line therapy for diffuse large B-cell lymphoma before receiving chimeric antigen receptor T-cell therapy.

During a live virtual event, Richard S. Finn, MD, discussed the process of diagnosing liver cancer after a CT scan detected tumors and whether a biopsy was needed.

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline recommended treatment options for patients with chronic lymphocytic leukemia based on a case scenario, with questions by Targeted Oncology.

During a live virtual event, Ravi Salgia, MD, PhD, discussed a possible approach for biopsy and molecular testing of a patient diagnosed with lung adenocarcinoma.

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 PROSPER trial of enzalutamide and the phase 3 ARAMIS trial of darolutamide in patients with castration-resistant prostate cancer.

During a live virtual event, Paolo Caimi, MD, discussed third-line treatment of a patient with diffuse large B-cell lymphoma and navigating obstacles to treatment.

Six months after a 75-year-old patient with castration-resistant prostate cancer shows undetectable PSA, the patient developed new hip pain and urinary frequency.

During a live virtual event, Beth A. Christian, MD, discussed data on third-line loncastuximab tesirine treatment in patients with diffuse large B-cell lymphoma and how to sequence treatments for patients who may receive CAR T-cell therapy.

Oncologists discuss a 59-year-old man with poorly differentiated adenocarcinoma of the lung.